Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: Potential implications in acute migraine treatment

Neuropharmacology

Volumn 42, Issue 4, 2002, Pages 568-576

  Moreno, M J ^a   Abounader, R ^a   Hebert E ^a   Doods, H ^b   Hamel, E ^a  

^a MCGILL UNIVERSITY   (Canada)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

CGRP8 37; BIBN4096BS; CGRP receptor antagonist; CGRP mediated dilation; Headache; Migraine; Trigeminovascular system

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE[8-37]; OLCEGEPANT; RECEPTOR BLOCKING AGENT; SEROTONIN CREATININE SULFATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BINDING SITE; BRAIN ARTERY; CATTLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN TISSUE; IC 50; MALE; MENINGEAL ARTERY; MIGRAINE; NONHUMAN; PIA ARTERY; PRIORITY JOURNAL;

ACUTE DISEASE; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CATTLE; CEREBRAL ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PIPERAZINES; QUINAZOLINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; VASODILATION;

EID: 0036226016     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00008-4     Document Type: Article

References (38)

1. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226
2. Some quantitative uses of drug antagonists
3. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: Similarity with human coronary artery
4. Pharmacological profile of BIBN4096BS: The first selective small molecule CGRP antagonist
5. Calcitonin gene-related peptide and cerebral blood vessels: Distribution and vasomotor effects
6. Peptide containing nerve fibres in human cerebral arteries: Immunocytochemistry, radioimmunoassay and in vitro pharmacology
7. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: Cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide
8. Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries
9. Trigeminal ganglion stimulation increases facial skin blood flow in the rat: A major role for calcitonin gene-related peptide
10. Differential vasodilator profile of calcitonin gene-related peptides in porcine large and small diameter coronary artery rings
11. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
12. Human in vivo evidence for trigeminovascular activation in cluster headache: Neuropeptide changes and effects of acute attacks therapies
13. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
14. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: Comparison with cerebral and temporal arteries
15. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase
16. Characterization of CGRP1 receptors in the guinea pig basilar artery
17. Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: Mediation by calcitonin gene-related peptide
18. Coronary side-effect potential of current and prospective antimigraine drugs
19. Effect of subcutaneous sumatriptan, a selective 5-HT1 agonist, on the systemic, pulmonary, and coronary circulation
20. RAMPs regulate the transport and ligand specificity of the calcitonin receptor-like receptor
21. Functional calcitonin gene-related peptide (CGRP) type 1 and adrenomedullin receptors in human trigeminal ganglia, brain vessels, cerebromicrovascular and/or astroglial cells in culture
22. CGRP-mediated dilations in human cerebral arteries are potently antagonized by BIBN4096BS, a selective CGRP receptor antagonist
23. Characterization of calcitonin gene-related peptide receptors and their receptor-activity modifying proteins (RAMPs) in human brain microvessels and astroglial cells in culture
24. Effects of adrenomedullin on rat cerebral arteries
25. Pharmacology of receptors for calcitonin gene-related peptide and amylin
26. 2 subdivision?
27. Characterization of CGRP1 and CGRP2 receptors
28. Expression of calcitonin receptor-like receptor and receptor-activity-modifying proteins in human cranial arteries
29. CGRP and adrenomedullin receptor populations in human cerebral arteries: In vitro pharmacological and molecular investigations in different artery sizes
30. Characterisation of the novel, non-peptide CGRP antagonist, BIBN4096BS and its tritiated radioanalogue in receptor binding studies
31. Functional characterisation of the CGRP antagonist BIBN4096BS, in SK-N-MC cells
32. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P
33. General theory of drug-receptor interactions. Drug-receptor interaction models. Calculation of drug parameters
34. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors
35. Sumatriptan in clinical practice: A 2-year review of 453 migraine patients
36. Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors
37. Receptors mediating CGRP-induced relaxation in the rat isolated thoracic aorta and porcine isolated coronary artery differentiated by h(alpha) CGRP(8-37)
38. 2,7]hCGRP-preferring receptor